Aerpio Pharmaceuticals, Inc. – NASDAQ:ARPO

Founder-led company

Aerpio Pharmaceuticals stock price today

$2.2
-11.32
-83.73%
Financial Health
0
1
2
3
4
5
6
7
8
9

Aerpio Pharmaceuticals stock price monthly change

+514.54%
month

Aerpio Pharmaceuticals stock price quarterly change

+514.54%
quarter

Aerpio Pharmaceuticals stock price yearly change

+569.31%
year

Aerpio Pharmaceuticals key metrics

Market Cap
 53.66M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -1.61
Revenue
 4.05M
EBITDA
 -40.71M
Income
 -59.51M
Revenue Q/Q
 -8.44%
Revenue Y/Y
 -25.59%
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 -1004.81%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Aerpio Pharmaceuticals stock price history

Aerpio Pharmaceuticals stock forecast

Aerpio Pharmaceuticals financial statements

Profit Margin

Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO): Profit margin
Dec 2022 1.05M -10.31M -981.35%
Mar 2023 796K -14.49M -1820.35%
Jun 2023 980K -3.54M -361.94%
Sep 2023 1.22M -31.16M -2543.76%
ARPO income statement history

Debt to Assets

Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO): Debt to assets
Dec 2022 95834000 59.75M 62.35%
Mar 2023 108779000 86.33M 79.36%
Jun 2023 101212000 82.06M 81.09%
Sep 2023 112761000 125.14M 110.98%
ARPO balance sheet history

Cash Flow

Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO): Cash Flow
Dec 2022 -10.48M 455K -500K
Mar 2023 -17.57M -2.00M 29.59M
Jun 2023 -12.06M -222K -368K
Sep 2023 -9.68M -3.51M 24.80M
ARPO cash flow history

Aerpio Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Aerpio Pharmaceuticals
Employees

Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO): Employee count
Aug 2023 12
Sep 2023 12
Oct 2023 12
Nov 2023 12
Dec 2023 12
Jan 2024 12
Feb 2024 12
Mar 2024 12
Apr 2024 12
May 2024 12
Jun 2024 12
Jul 2024 12

Aerpio Pharmaceuticals other data

Aerpio Pharmaceuticals
Insider Trading

Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO): Insider trades (number of shares)
Period Buy Sel
Dec 2020 0 21400
Aug 2021 1789400 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
DALAL ANUPAM director
 Common Stock 1,529,402 $13.08 $19,999,990
Purchase
CASTELEIN CALEY director
 Common Stock 259,998 $13.08 $3,399,994
Sale
ORBIMED ADVISORS LLC 10 percent owner
 Common Stock 21,400 $0.96 $20,544
Purchase
GARDNER JOSEPH H. director, officer.. Common Stock 5,000 N/A N/A
Purchase
GARDNER JOSEPH H. director, officer.. Common Stock 5,000 N/A N/A
Sale
NOVARTIS BIOVENTURES LTD 10 percent owner
 Common Stock 138,704 N/A N/A
Sale
NOVARTIS BIOVENTURES LTD 10 percent owner
 Common Stock 563,096 $1.03 $579,989
Sale
NOVARTIS BIOVENTURES LTD 10 percent owner
 Common Stock 16,403 N/A N/A
Sale
NOVARTIS BIOVENTURES LTD 10 percent owner
 Common Stock 27,554 $1.03 $28,381
Sale
NOVARTIS BIOVENTURES LTD 10 percent owner
 Common Stock 7,100 N/A N/A
ARPO insider trading transactions

Aerpio Pharmaceuticals
Patents

Patent
Application
Filling date: 12 Nov 2020 Issue date: 21 Apr 2022
Application
Filling date: 21 Jun 2021 Issue date: 20 Jan 2022
Application
Filling date: 15 Jan 2021 Issue date: 16 Dec 2021
Application
Filling date: 7 Jan 2021 Issue date: 15 Jul 2021
Application
Filling date: 10 Dec 2020 Issue date: 10 Jun 2021
Application
Filling date: 28 Oct 2020 Issue date: 20 May 2021
Application
Filling date: 2 Oct 2020 Issue date: 6 May 2021
Application
Filling date: 21 Sep 2020 Issue date: 1 Apr 2021
Grant
Filling date: 22 Sep 2016 Issue date: 23 Mar 2021
Grant
Filling date: 23 Sep 2019 Issue date: 19 Jan 2021
ARPO patents

Aerpio Pharmaceuticals
Earnings Call Transcripts

Quarter Transcript
Q2 2020 12 Aug 2020 Q2 2020 Earnings Call Transcript
Q4 2019 16 Mar 2020 Q4 2019 Earnings Call Transcript
Q4 2018 5 Mar 2019 Q4 2018 Earnings Call Transcript
Q3 2018 10 Nov 2018 Q3 2018 Earnings Call Transcript
ARPO earnings call transcripts

Frequently Asked Questions (FAQ)

  • What's the price of Aerpio Pharmaceuticals stock today?

    One share of Aerpio Pharmaceuticals stock can currently be purchased for approximately $2.2.

  • When is Aerpio Pharmaceuticals's next earnings date?

    Unfortunately, Aerpio Pharmaceuticals's (ARPO) next earnings date is currently unknown.

  • Does Aerpio Pharmaceuticals pay dividends?

    No, Aerpio Pharmaceuticals does not pay dividends.

  • How much money does Aerpio Pharmaceuticals make?

    Aerpio Pharmaceuticals has a market capitalization of 53.66M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 23.11% to 5.51M US dollars.

  • What is Aerpio Pharmaceuticals's stock symbol?

    Aerpio Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ARPO".

  • What is Aerpio Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Aerpio Pharmaceuticals?

    Shares of Aerpio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Aerpio Pharmaceuticals's key executives?

    Aerpio Pharmaceuticals's management team includes the following people:

    • Dr. Joseph H. Gardner Founder, Pres, Principal Executive Officer & Director(age: 69, pay: $752,400)
    • Ms. Regina Marek Principal Financial Officer, Principal Accounting Officer & Vice President of Fin.(age: 56, pay: $447,120)
    • Dr. Dhaval Desai Chief Strategy Officer

  • Is Aerpio Pharmaceuticals founder-led company?

    Yes, Aerpio Pharmaceuticals is a company led by its founder Dr. Joseph H. Gardner.

  • How many employees does Aerpio Pharmaceuticals have?

    As Jul 2024, Aerpio Pharmaceuticals employs 12 workers.

  • When Aerpio Pharmaceuticals went public?

    Aerpio Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 26 Jun 2018.

  • What is Aerpio Pharmaceuticals's official website?

    The official website for Aerpio Pharmaceuticals is aerpio.com.

  • Where are Aerpio Pharmaceuticals's headquarters?

    Aerpio Pharmaceuticals is headquartered at 9987 Carver Rd, Blue Ash, OHIO.

  • How can i contact Aerpio Pharmaceuticals?

    Aerpio Pharmaceuticals's mailing address is 9987 Carver Rd, Blue Ash, OHIO and company can be reached via phone at +1 513 985 1920.

Aerpio Pharmaceuticals company profile:

Aerpio Pharmaceuticals, Inc.

aerpio.com
Exchange:

NASDAQ

Full time employees:

12

Industry:

Biotechnology

Sector:

Healthcare

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.

+1 513 985 1920
9987 Carver Rd
Blue Ash, OHIO

CIK: 0001422142
ISIN: US00810B1052
CUSIP: 00810B105